Evidence map›Paper›PMID 39279443›Full record

ArticleHaematologica2025

A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myeloma.

Josefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, Dana Hoser, Martin Vaegler, Hana Rauschenbach, Ioannis Anagnostopoulos, Korinna Jöhrens, Vivian Scheuplein, Elisa Kieback and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Josefine KrügerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Matthias ObenausDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Igor Wolfgang BlauDepartment of Hematology, Oncology and Cancer Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin.
Dana HoserInstitute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin.
Martin VaeglerExperimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, 13125 Berlin.
Hana RauschenbachExperimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, 13125 Berlin.
Ioannis AnagnostopoulosInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Korinna JöhrensInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Vivian ScheupleinMax-Delbrück-Center for Molecular Medicine, 13125 Berlin.
Elisa KiebackMax-Delbrück-Center for Molecular Medicine, 13125 Berlin.
Judith BöhmeInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Ann-Christin Von BrünneckInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin.
Jan KrönkeDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin.
Antonia BusseDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin.
Gerald WillimskyInstitute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany; German Cancer Research Center (DKFZ), 69120 Heidelberg.
Thomas BlankensteinMax-Delbrück-Center for Molecular Medicine, 13125 Berlin.
Antonio PezzuttoDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin. ulrich.keller@charite.de.
Axel NogaiDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin. nogai@onkologie-tiergarten.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39279443
PMCPMC11694112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.